

Supplementary Table 2. Detailed information regarding the number of patients and cut-off values for VCTE for staging liver fibrosis in studies included in the meta-analysis

Disease	Author (year)	Significant fibrosis (\geq F2)		Advanced fibrosis (\geq F3)		Cirrhosis (F4)	
		No. of patients	Cut-off value (kPa)	No. of patients	Cut-off value (kPa)	No. of patients	Cut-off value (kPa)
PBC	Gómez-Dominguez et al. ¹⁹ (2008)	-	-	16	14.7	-	15.6
	Floreani et al. ¹⁸ (2011)	88	5.9	50	7.6	17	11.4
	Corpechot et al. ¹⁷ (2012)	52	8.8	30	10.7	15	16.9
	Koizumi et al. ²⁰ (2017)	17	16.0	13	17.9	6	25.1
	Milovanović et al. ²¹ (2018)	-	-	49	9.9	-	-
	Osman et al. ²² (2021)	52	7.0	24	7.5	8	14.4
AIH	Hartl et al. ²⁵ (2016)	22	5.8	11	10.4	6	16.0
	Hartl et al. ²⁵ (2016)	34	5.8	22	10.4	14	16.0
	Anastasiou et al. ²³ (2016)	44	10.05	29	12.1	15	19.0
	Xu et al. ²⁷ (2017)	84	6.45	50	8.75	23	12.5
	Guo et al. ²⁴ (2017)	78	6.27	54	8.18	24	12.67
	Paranaguá-Vezozzo et al. ²⁶ (2023)	26	6.3	18	8.7	8	12.3
PSC	Corpechot et al. ²⁸ (2014)	32	7.4	15	9.6	9	14.4
	Krawczyk et al. ³⁰ (2017)	-	-	-	-	19	13.7
	Ehlken et al. ²⁹ (2019)	27 (43.5)	8.8	20 (32.3)	9.6	16 (25.8)	14.4

VCTE, vibration-controlled transient elastography; PBC, primary biliary cholangitis; AIH, autoimmune hepatitis; PSC, primary sclerosing cholangitis.